Oncotarget is a peer reviewed open access medical journal published weekly. It covers all oncology research related articles. The journal was founded in 2010 and is printed by Impact Journal. Mikhail Blagosklonny and Andrei V. Gudkov are the editors-in-chief. The journal is applauded for being creative, constructive, insightful, and punctual. It has multiple peer reviews. The peer review has enabled Oncotarget authors to do a very influential research. The Oncotarget accepts papers on topics such as Endocrinology, Pharmacology, Neuroscience, Cardiology, Cell Biology and Metabolism which are beyond Oncology. It is considered as one of the best multidisciplinary journals with free access to researchers. Oncotarget provides online papers in weekly issues. The public can print issue or paper at a special demand.
The mission of this renowned journal is to make scientific results easily and widely accessible. They intend to leverage on the impact of the research through thorough and insightful peer reviews. The journal allows superb discoveries to be shared widely and faster. The journal has helped to eliminate the barrier between specialties and to connect various fields of biomedical sciences. It supports applications of basic and clinical science to fight disease. Through the leadership of the most eminent scientists, the Oncotarget journal assists researchers to contribute towards the progress and development of science. They are aiming for a life free from disease.
Mikhail Blagosklonny is a former professor of oncology at the Roswell Park Cancer Institute in New York. He is a scientist and focuses his study on cancer and aging. He attended First Pavlov State Medical University of St. Peterburg where he earned his M.D. in internal medicine and Ph.D. in experimental medicine and cardiology. In 2002, he was appointed as an associate professor of medicine at New York medical college, Valhalla, NY. He then became a senior scientist at Ordway Research Institute, Albany, New York. In 2009, he became a professor of oncology at Roswell Park Cancer Institute. He is interested in researching cancer therapies that protect normal cells from damage and mechanisms beneath aging and anti-aging drugs. He is editor-in-chief of Oncotarget, Aging and Cell Cycle.